Prevention of venous thromboembolism in ambulatory patients with cancer

ESMO Open

article

Alok A. Khorana¹  Alexander T. Cohen²  Marc Carrier³  Guy Meyer⁴  Ingrid Pabinger⁵  Petr Kavan⁶  PhilipS Wells³ 

[1] Department of Hematology and Medical Oncology, Taussig Cancer Institute, Cleveland Clinic;Department of Haematological Medicine, Guys and St Thomas’ Hospitals, King"s College London;Department of Medicine, University of Ottawa, Ottawa Hospital Research Institute at the University of Ottawa;Hôpital Européen Georges-Pompidou AP-HP, Université Paris Descartes;Comprehensive Cancer Center, Medical University of Vienna;Department of Oncology, Jewish General Hospital, McGill University

关键词: anticoagulant;    cancer-associated thrombosis;    direct oral anticoagulant;    low molecular weight heparin;    venous thromboembolism;    thromboprophylaxis;   

DOI  :  10.1136/esmoopen-2020-000948

学科分类：社会科学、人文和艺术（综合）

来源: BMJ Publishing Group

【 摘 要 】

Patients with cancer are at high risk of venous thromboembolic events, and this risk can be further increased in patients with certain cancer types and by cancer treatments. Guidelines on the prevention of cancer-associated thrombosis (CAT) recommend thromboprophylaxis for hospitalised patients; however, this is not routinely recommended for ambulatory patients receiving chemotherapy and is limited to specified high-risk patients. Identification of the ambulatory patients at risk of CAT who would most benefit from anticoagulant therapy is therefore critical to reduce the incidence of this complication. For patients receiving thromboprophylaxis for CAT, treatment options include low molecular weight heparin, acetylsalicylic acid, warfarin or direct oral anticoagulants (apixaban or rivaroxaban), dependent on the cancer type and cancer treatment regimen. This review discusses emerging clinical trial data and their potential clinical impact.

【 授权许可】

CC BY|CC BY-NC-ND